A REVIEW OF HEALTH TECHNOLOGY APPRAISALS: CASE STUDIES IN ONCOLOGY

2012 ◽  
Vol 29 (1) ◽  
pp. 101-109 ◽  
Author(s):  
Koonal Kirit Shah ◽  
Jorge Mestre-Ferrandiz ◽  
Adrian Towse ◽  
Emily Nash Smyth

Pharmaceutical manufacturers, regulators, patients, providers, and payers all have a shared interest in improving health outcomes for patients with cancer. Each plays an important role in helping to achieve this common goal. Pharmaceutical manufacturers seek to develop new medicines that are supported by robust and clinically meaningful evidence of their safety, efficacy, and effectiveness. Regulators authorize these medicines based on evaluations of their safety and efficacy. Patients and providers together make treatment decisions and desire access to the most effective treatment options. Payers appraise new medicines with the goal of ensuring access to those medicines that constitute efficient uses of healthcare expenditure. Profits generated from the sale of the medicines provide a return to the manufacturer, which helps to drive continued research and development in an effort to improve patient health outcomes and societal well-being. Many payers have initiated health technology assessment (HTA) activities to inform decision making in light of the rising costs of health care. Given the financial constraints imposed as a result of the global economic crisis, HTAs are likely to become increasingly important as payers seek value for money solutions to major health problems. Successful collaboration and aligning incentives across stakeholders is critical to ensuring that patients are able to access the most effective medicines.

Blood ◽  
2020 ◽  
Vol 136 (Supplement 1) ◽  
pp. 16-17
Author(s):  
David A. Sallman ◽  
Tracey Iraca ◽  
Casey L. O'Connell ◽  
Rafael Bejar ◽  
Sandra Kurtin

Background: Patients with MDS continue to report gaps in knowledge, particularly where understanding of disease risk, prognosis and treatment options are concerned.1 A recent online social media survey on experiences in myelodysplastic syndromes revealed that patients/caregivers' (n=127) have a general lack of information about MDS and insufficient knowledge regarding treatment options and are unable to make fully informed decisions.2 Efforts to improve patient and caregiver understanding of MDS, including treatment options, are critical to individualized treatment planning and shared decision-making. MDS patients commonly use multimedia and online resources to seek disease information.3 The MDSF introduced an online 'animated,' visual format educational program in July 2018 aimed at improving patient and caregiver knowledge.4 Evaluation of this project, including determining changes in patient knowledge and intent-to-implement a change in behavior are described as parameters of advancing and benefiting health outcomes. Methods: An Animated Patient's Guide to MDS (APG), a multimedia educational initiative was launched globally in July 2018. Recruitment was conducted via search engine marketing, social media promotions and email campaigns to MDS patients, caregivers and oncology provider audiences. Video views, duration of use, and learner responses to questions on the APG website were collected from July 2018 to July 2020 (24 months). Total APG views, most frequently viewed MDS animations and MDS expert videos were monitored on the website and on You Tube, to measure learner responses to outcome-based questions, and learner intent-to-implement changes. Results: A total of 151,231 views, including 58,947 unique visitors visited the APG online resource. Of these, 81% were from the U.S. and 19% from other countries (> 50 countries). Unique visitors from U.S. consisted of 28,171 patients, 15,279 family/caregivers, and 1,910 health providers. Among responses indicating a 'commitment to change', 96% reported they will 'use new information learned to better self-manage their MDS' (n = 917), 93% reported they 'will discuss information learned with their doctor' (n = 355), and 97% reported they 'plan to discuss MDS treatment options with their doctor' (n = 734). Patients who reported they 'learned new information about MDS' identified that they 'learned new general information about MDS' (95%, n = 193), 'learned new information about the diagnosis of MDS' (86%, n = 195), 'learned about new treatment options for MDS' (89%, n = 195), 'learned about new information related to bone marrow transplant in MDS' (85%, n = 177) and intended to 'ask their doctor about how to take part in healthcare decisions' (96%, n = 187). Conclusion: Multimedia education, including visual 'animated' formats, tailored to the needs of MDS patients has the potential to provide effective learning, increase knowledge and improve engagement in shared decision-making. Ongoing monitoring and further analysis of this multimedia educational resource for MDS patients will be necessary to understand how tailored education provided via this format impacts and benefits patient health outcomes. References: 1. Kurtin, S., Chang, E., & Bently, T. (2015). MDS patient characteristics associated with use of disease-modifying therapy: results of a patient survey. The International MDS Symposia, Washington, D.C. 2. Booth, A., Bell, T., Halhol, S., Pan, S., Welch, V., Merinopoulou, E., Lambrelli, D., Cox, A. Using Social Media to Uncover Treatment Experiences and Decisions in Patients with Acute Myeloid Leukemia or Myelodysplastic Syndrome Who Are Ineligible for Intensive Chemotherapy. J Med Internet Res 2019 Nov; 21(11) e-14285 3. Kurtin, S., Harrison, L., Iraca, T., Hassan, A., Nichols, A. Health Technology Engagement and Communicative Health Literacy in Older Adults MDS Patients. Myelodysplastic Syndromes, 15th International Symposia on Myelodysplastic Syndromes. Copenhagen. May 8-1, 2019. Poster presentation. 4. MDS Foundation, Inc. and Mechanisms in Medicine Inc. (2019-06-26). You And MDS: An Animated Patient's Guide to Myelodysplastic Syndromes. www.YouAndMDS.com Disclosures Sallman: Agios, Bristol Myers Squibb, Celyad Oncology, Incyte, Intellia Therapeutics, Kite Pharma, Novartis, Syndax: Consultancy; Celgene, Jazz Pharma: Research Funding. Iraca:MDS Foundation: Membership on an entity's Board of Directors or advisory committees. Bejar:Celgene/BMS: Honoraria, Research Funding; Forty-Seven/Gilead: Honoraria; Genoptix/NeoGenomics: Honoraria; AbbVie/Genentech: Honoraria; Daiichi-Sankyo: Honoraria; Aptose Biosciences: Current Employment; Takeda: Honoraria, Research Funding; Astex/Otsuka: Honoraria. Kurtin:MDS Foundation: Membership on an entity's Board of Directors or advisory committees.


2013 ◽  
Vol 31 (15_suppl) ◽  
pp. e19104-e19104
Author(s):  
Tom Bregartner

e19104 Background: The Validation Model is an educational series built on the concept of strengthening education by incorporating the patient perspective. After conducting two iterations of the Validation Model to educate oncologists in the treatment of NSCLC, Quintiles Medical Education was able to demonstrate that CME can lead to improved patient health outcomes by changing physician behaviors in practice. Educational measurement tools, including chart audits, revealed an increase in tumor histology and EGFR mutation testing. Histologic and molecular marker testing leads to optimization of treatment based on tumor pathology and genotype, respectively, as per NCCN guidelines. Personalization of treatment according to guidelines results in improved health outcomes. Methods: The Validation Model consisted of 6 educational activities for which efficacy was measured by conducting pre- and post-tests of knowledge and clinical competence among participants. Participants were then asked to complete a follow-up survey which was designed to determine if specific practices had been implemented since participation. The self-self reported behavioral data was validated by the distribution of patient surveys, designed to measure patient satisfaction and expectation with care, and chart audits, designed to determine the actual practice habits of the participating practitioners. Results: More than 500 participants have completed all 6 of the educational activities. The activities have demonstrated improved knowledge and competence in the educational setting and changes to clinical practice and, as a result, patient health outcomes. Conclusions: CME can be used as an effective tool to improve patient health outcomes in the treatment of NSCLC.


2016 ◽  
Vol 41 (3) ◽  
pp. 191-195 ◽  
Author(s):  
Victoria M. Rizzo ◽  
Jeannine M. Rowe ◽  
Gayle Shier Kricke ◽  
Kate Krajci ◽  
Robyn Golden

2021 ◽  
Vol 10 (22) ◽  
pp. 5284
Author(s):  
Michael Feehan ◽  
Leah A. Owen ◽  
Ian M. McKinnon ◽  
Margaret M. DeAngelis

The use of artificial intelligence (AI) and machine learning (ML) in clinical care offers great promise to improve patient health outcomes and reduce health inequity across patient populations. However, inherent biases in these applications, and the subsequent potential risk of harm can limit current use. Multi-modal workflows designed to minimize these limitations in the development, implementation, and evaluation of ML systems in real-world settings are needed to improve efficacy while reducing bias and the risk of potential harms. Comprehensive consideration of rapidly evolving AI technologies and the inherent risks of bias, the expanding volume and nature of data sources, and the evolving regulatory landscapes, can contribute meaningfully to the development of AI-enhanced clinical decision making and the reduction in health inequity.


2020 ◽  
Vol 35 (7) ◽  
pp. 292-294
Author(s):  
Shane Jackson

In early 2019, a report from Australia documented significant data about the harms associated with medication use. This editorial reports on the Australian government's changes to cycles-of-care and telehealth reviews, changes made to improve patient health outcomes, and payment to pharmacists—information that may be useful to other countries.


Author(s):  
Véronique Nabelsi

Healthcare organizations in many countries are compelled to pursue drastic supply cost reductions, while continuing to improve patient health outcomes, as they must meet ever increasing economic and performance pressures brought on by changes in national health policies. As demonstrated in many other industries, these improvements require more integrated Supply Chain Management (SCM) practices, processes, and systems. The author develops a strategic framework for Customer-Oriented or Patient-Driven SCM, integrating the evolving economics of the healthcare industry and the emerging dynamics of global supply chains. The chapter focuses on modern SCM approaches such as agile and lean supply chains, in order to efficiently realign hospitals and their Material Management Systems (MMS) on patient health outcomes.


2015 ◽  
Vol 8s1 ◽  
pp. NMI.S29523 ◽  
Author(s):  
Iris J. Grooten ◽  
Tessa J. Roseboom ◽  
Rebecca C. Painter

Nausea and occasional vomiting in early pregnancy (NVP) are common. When vomiting is severe or protracted, it is referred to as hyperemesis gravidarum (HG). HG affects up to 3% of pregnancies and is characterized by weight loss, dehydration, electrolyte imbalance, and the need for hospital admission. HG has significant consequences for maternal well-being, is associated with adverse birth outcomes, and leads to major health care costs. Treatment options are symptomatic, hampered by the lack of evidence-based options including studies on nutritional interventions. One of the reasons for this lack of evidence is the use of a broad range of definitions and outcome measures. An internationally accepted definition and the formulation of core outcomes would facilitate meta-analysis of trial results and implementation of evidence in guidelines to ultimately improve patient care.


2020 ◽  
Vol 34 (1) ◽  
pp. 26-28
Author(s):  
Mike Lapaine

Healthcare institutions have for some time pursued the Triple Aim: improve patient health outcomes, improve patient experience, and reduce costs. More recently, it has been recognized that the “missing piece” of success is to improve the experience of their clinicians in order to improve the three aims. The leadership of Bluewater Health has been using the Quadruple Aim since 2016 and, by working to improve employee engagement, has succeeded in also delivering exemplary care that has improved patient outcomes and experience and reduced costs.


Sign in / Sign up

Export Citation Format

Share Document